MiR‐320 promotes B cell proliferation and the production of aberrant glycosylated IgA1 in IgA nephropathy

Li, Chunmei; Shi, Jie; Zhao, Yu

doi:10.1002/jcb.26628

Cited by 27 publications

(20 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43 Overexpression of hsa-miR-320 promotes B-cell proliferation through suppressing Phosphatase and tensin homolog(PTEN) expression and promotes cyclin D1 expression. 44 Our data also confirmed that high expression of hsa-miR-320d, hsa-miR-320c, and hsa-miR-320b has a negative prognosis and associated with bad response to anti-PD-1 treatment in patients with NSCLC. The observation of downregulated hsa-miR-125b-5p in PR-pre group also supported the role of hsa-miR-125b-5p as a T-cell suppressor in another study.…”

Section: Open Accesssupporting

confidence: 82%

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy inEGFR/ALKwild-type advanced non-small cell lung cancer

Peng

Yu²,

Wu³

et al. 2020

J Immunother Cancer

137

View full text Add to dashboard Cite

BackgroundImmunotherapy has become an important treatment option for patients with advanced non-small cell lung cancer (NSCLC). At present, none of these existing biomarkers can effectively stratify true responders and there is an urgent need for identifying novel biomarkers. Exosomes derived from the serum of patients with cancer have been proven to be reliable markers for cancer diagnosis. Here, we explored the possibility of using plasma-derived exosomal microRNAs as potential biomarkers for optimal selection of patients with advancedEGFR/ALKnegative NSCLC to immunotherapy.MethodsFrom June 2017 to February 2019, 30 patients with advancedEGFR/ALKwild-type (WT) NSCLC who received PD-1/PD-L1 inhibitors were enrolled. The efficacy evaluation was conducted after every three cycles of treatment according to RECIST 1.1. Plasma samples of these patients were collected before the administration of PD-1/PD-L1 inhibitors as baseline, and after every three cycles if the patients achieved partial response (PR) or complete response. Plasma from seven healthy individuals was also collected as normal control. Exosomes were prepared by ultracentrifugation followed by total RNA extraction, and exosome-derived miRNAs were profiled using small RNA next-generation sequencing followed by differential expression analysis.ResultsIn order to identify biomarker for better response, all five patients who achieved PR and four patients with progressive disease (PD) at efficacy evaluation were included for differential expression analysis. Based on unsupervised hierarchical clustering, exosomal miRNA expression profile was significantly altered in patients with NSCLC compared with normal controls with a total of 155 differentially expressed exosomal miRNAs. Interestingly, hsa-miR-320d, hsa-miR-320c, and hsa-miR-320b were identified significantly upregulated in the PD groups compared with the PR group at baseline before the treatment. In addition, we identified that hsa-miR-125b-5p, a T-cell suppressor, showed a trend of increased expression in the PD group at baseline and was significantly downregulated in the post-treatment plasma exosomes compared with pre-treatment samples of the PR patients.ConclusionPatients with NSCLC represent unique plasma exosomal miRNA profiles. Hsa-miR-320d, hsa-miR-320c, and hsa-miR-320b were identified as potential biomarkers for predicting the efficacy of immunotherapy in advanced NSCLCs. When T-cell suppressor hsa-miR-125b-5p was downregulated during the treatment, the patients may obtain increased T-cell function and respond well to immunotherapy.

show abstract

Section: Open Accesssupporting

confidence: 82%

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy inEGFR/ALKwild-type advanced non-small cell lung cancer

Peng

Yu²,

Wu³

et al. 2020

J Immunother Cancer

137

View full text Add to dashboard Cite

show abstract

“…U6 is highly conserved among species 12 and relatively stable in different tissues and cells from the same organism. U6 is one of the most commonly used miRNA housekeeping genes and is often used in the study of IgAN kidney tissue and renal cell lines 18 , 21 , 22 . Currently, U6 is the most widely using reference gene in urinary sediment miRNAs studies 4 – 8 , 19 , 23 that are primarily based on studies using tissue samples and cell lines 17 , 18 .…”

Section: Discussionmentioning

confidence: 99%

U6 can be used as a housekeeping gene for urinary sediment miRNA studies of IgA nephropathy

Duan

Cai

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Recent studies have indicated that urinary sediment miRNAs not only are able to serve as non-invasive diagnostic biomarkers for IgA nephropathy (IgAN) but may also be closely related to several clinical and pathological indicators. However, the lack of a suitable internal reference miRNA has hampered research into urinary sediment miRNAs. To date, U6 has been used as a reference gene in urinary sediment miRNA studies mostly based on the results from studies using tissue samples and cell lines. In a total of 330 IgAN patients, 164 disease control patients and 130 normal control patients, there was no significant difference in U6 levels. We also compared the U6 levels in different types of primary glomerular disease groups (IgA nephropathy, membranous nephropathy, minimal change nephrosis and focal segmental glomerular sclerosis). The results confirmed that there was no significant difference in the expression of U6 in different primary glomerular disease groups. Moreover, treatment had no significant effect on the expression levels of U6 in IgA nephropathy. Therefore, U6 is an excellent housekeeping gene for urinary sediment miRNA studies of IgA nephropathy.

show abstract

“…In similar experiments, having discovered that upregulated miR-320 expression in the renal tissue and urine of IgAN patients was accompanied by reduced expression of Cosmc, Li et al overexpressed miR-320 in B cells and discovered that this had the effect of downregulating Cosmc expression as well as inducing B cell proliferation [65], again implicating this miR in the regulation of IgA1 O-glycosylation. Potential miR interactions resulting in the galactosylation of IgA are illustrated in Figure 4.…”

Section: B Cellsmentioning

confidence: 97%

The Non-Coding RNA Landscape in IgA Nephropathy—Where Are We in 2021?

Pawluczyk

Selvaskandan

Barratt

2021

JCM

View full text Add to dashboard Cite

IgA nephropathy (IgAN) is the most commonly diagnosed primary glomerulonephritis worldwide. It is a slow progressing disease with approximately 30% of cases reaching end-stage kidney disease within 20 years of diagnosis. It is currently only diagnosed by an invasive biopsy and treatment options are limited. However, the current surge in interest in RNA interference is opening up new horizons for the use of this new technology in the field of IgAN management. A greater understanding of the fundamentals of RNA interference offers exciting possibilities both for biomarker discovery and, more importantly, for novel therapeutic approaches to target key pathogenic pathways in IgAN. This review aims to summarise the RNA interference literature in the context of microRNAs and their association with the multifaceted aspects of IgA nephropathy.

show abstract

MiR‐320 promotes B cell proliferation and the production of aberrant glycosylated IgA1 in IgA nephropathy

Cited by 27 publications

References 41 publications

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy inEGFR/ALKwild-type advanced non-small cell lung cancer

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy inEGFR/ALKwild-type advanced non-small cell lung cancer

U6 can be used as a housekeeping gene for urinary sediment miRNA studies of IgA nephropathy

The Non-Coding RNA Landscape in IgA Nephropathy—Where Are We in 2021?

Contact Info

Product

Resources

About